Condition: Short-coupled Ventricular Fibrillation · Idiopathic Ventricular Fibrillation · Sponsor: Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Short-coupled ventricular fibrillation (SCVF) is a lethal, primary electrical disorder and an important cause of unexplained cardiac arrest.1 Recent work from our group suggests that a substantial proportion of SCVF cases is associated to circulating autoantibodies targeting TREK-1, a cardiac potassium channel, resulting in an abnormal gain-of-function which is the prerequisite for the SCVF phenotype.2 This proposal is a translational multicenter study to validate anti-TREK-1 autoantibodies as a diagnostic and prognostic biomarker in a large, diversified cohort of SCVF patients (Figure 1). Functional, cellular experiments in patient-derived hiPSC cardiomyocytes and Purkinje cells will be performed to explore the cell type-specific role of TREK-1 in arrhythmogenesis, while single-nuclear RNA sequencing (snRNA-seq) will allow us to establish the transcriptomic profile (Figure 1). These results will identify the cellular substrate for SCVF.
This description comes directly from the study's public registry record.
Marina Sanchez, PhD · +14186568711 · marina.sanchez@criucpq.ulaval.ca
Paule Banville, Study coordinator · +14186568711 · paule.banville@criucpq.ulaval.ca
Always discuss trial participation with your own doctor first.
| St-Paul's Hospital - University of British Columbia | Vancouver, British Columbia, Canada | Not Yet Recruiting |
| PHRI | Hamilton, Ontario, Canada | Active Not Recruiting |
| Ottawa Heart Center | Ottawa, Ontario, Canada | Not Yet Recruiting |
| Institut universitaire de cardiologie et pneumologie de Québec | Québec, Quebec, Canada | Recruiting |
| Amsterdam University Medical Center | Amsterdam, Netherlands | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06943365